Chikungunya

Virus/Vector — shared ground with dengue

ssRNA(+), Togaviridae, genus Alphavirus (DIFFERENT family from dengue/JE’s Flaviviridae, despite overlap below). Vector: SAME Aedes mosquitoes (aegypti, albopictus) as dengue → CO-CIRCULATES same areas/seasons → overlapping outbreaks, diagnostic confusion (similar acute febrile presentation) — distinguishing the two = high-yield skill.

Clinical — defining contrast vs dengue

High fever + SEVERE, often debilitating POLYARTHRALGIA/ARTHRITIS (classically small joints hands/feet, wrists, ankles; larger joints too) — defining signature. KEY CONTRAST vs dengue: chikungunya joint symptoms MORE SEVERE/PROMINENT/ARTHRITIC than dengue’s myalgia/mild arthralgia. Etymology: “chikungunya” = Makonde word “that which bends up”/“walk bent over” — describes contorted posture from joint pain (reinforces defining feature). Maculopapular rash: common accompanying feature. IMPORTANT: does NOT typically cause severe hemorrhagic complications or plasma-leakage/shock syndrome (unlike dengue) — lacks dengue’s most feared severe complications despite acute severity.

Chronic Arthralgia — distinctive long-term feature (testable)

Substantial proportion (sometimes majority in some outbreak cohorts) develop PERSISTENT chronic arthralgia/arthritis lasting MONTHS-YEARS after acute illness resolves. No comparable counterpart in dengue natural history — significant distinctive long-term morbidity.

Diagnosis

Similar phase-dependent logic to dengue: RT-PCR/antigen (early viremic, ~1st week) + serology IgM/IgG ELISA (later). Given clinical overlap + co-circulation with dengue: SPECIFIC LAB CONFIRMATION often necessary to distinguish reliably — clinical picture (severe arthralgia, no hemorrhagic complications) provides useful but not definitive guidance.

Treatment

SUPPORTIVE ONLY — analgesia (same NSAID-caution principle as dengue given diagnostic uncertainty early + dengue’s bleeding risk vulnerability), rest, hydration. NO specific antiviral or licensed vaccine (vaccine development active/ongoing). Prevention: VECTOR CONTROL (same Aedes breeding sites as dengue) = shared primary strategy given shared vector ecology.

The Virus and Its Vector — Genuinely Shared Ground With Dengue

Chikungunya virus, a single-stranded positive-sense RNA virus of the Togaviridae family (genus Alphavirus — genuinely, specifically worth noting as a different viral family from dengue and Japanese encephalitis’s Flaviviridae, despite the substantial epidemiological overlap described below), is transmitted by the same Aedes mosquito vectors (Aedes aegypti and Aedes albopictus) responsible for dengue transmission (see Dengue Fever and Viral Haemorrhagic Fever) — this shared vector is genuinely, practically important, since it means chikungunya and dengue co-circulate in the same geographic areas and transmission seasons, frequently causing genuinely overlapping outbreaks and real diagnostic confusion given their substantially similar acute febrile presentations, making the ability to clinically and laboratory-distinguish the two diseases a real, high-yield, specifically testable skill.

Clinical Manifestations — The Defining Contrast With Dengue

Chikungunya presents with acute-onset high fever and, genuinely, specifically and defining for this disease, severe, often debilitating polyarthralgia/arthritis — joint pain affecting multiple joints (classically small joints of the hands and feet, wrists, and ankles, though larger joints can also be involved), frequently severe enough to significantly limit mobility and function during the acute illness. This severe joint involvement is precisely the disease’s defining clinical signature and the genuinely most useful clinical point of contrast with dengue: while dengue can cause myalgia and some arthralgia, chikungunya’s joint symptoms are characteristically more severe, more prominent, and more specifically arthritic in character — indeed, the name “chikungunya” itself derives from a Makonde (East African) word meaning roughly “that which bends up” or “to walk bent over,” directly describing the contorted posture affected patients classically adopt from severe joint pain, a genuinely worthwhile etymological point that reinforces the disease’s defining clinical feature. A maculopapular rash is also a common accompanying feature. Critically, and genuinely, specifically important: unlike dengue, chikungunya does not typically cause severe haemorrhagic complications or a comparable plasma-leakage/shock syndrome — a real, important point of contrast, since chikungunya, despite its acute severity, generally lacks dengue’s most feared severe-disease complications (dengue haemorrhagic fever/dengue shock syndrome).

Chronic Arthralgia — A Genuinely Important, Distinctive Long-Term Feature

A genuinely, specifically important, testable point distinguishing chikungunya from dengue in its natural history: a substantial proportion of chikungunya patients — genuinely, notably, sometimes a majority in some reported outbreak cohorts — develop persistent, chronic arthralgia/arthritis lasting months to, in some cases, years after the acute illness has otherwise resolved, a real, clinically significant long-term morbidity burden that has no comparable counterpart in dengue’s natural history and represents one of chikungunya’s most distinctive, genuinely testable clinical features.

Diagnosis

Diagnosis follows a broadly similar general approach to dengue’s phase-dependent diagnostic logic (see Dengue Fever and Viral Haemorrhagic Fever): RT-PCR or viral antigen detection during the early viraemic phase (roughly the first week of illness), and serology (IgM/IgG ELISA) becoming positive and useful somewhat later in the course — genuinely worth remembering that, given the substantial clinical overlap and co-circulation with dengue described above, specific laboratory confirmation is often necessary to reliably distinguish the two diseases in an individual patient, rather than relying on clinical picture alone, even though the severe-arthralgia/absence-of-haemorrhagic-complications pattern described above provides real, useful clinical guidance favouring one diagnosis over the other.

Treatment

Management is entirely supportive — analgesia (with the same NSAID-caution principle relevant in dengue co-endemic settings worth remembering, given the diagnostic uncertainty often present early in illness before dengue can be confidently excluded, and dengue’s specific vulnerability to NSAID-related bleeding risk), rest, and hydration — since no specific antiviral treatment or licensed vaccine exists for chikungunya (though vaccine development is an active area, genuinely worth noting as a point of ongoing progress distinct from the currently-available toolkit), leaving vector control (targeting the same Aedes mosquito breeding sites relevant to dengue prevention) as the primary, shared public-health prevention strategy for both diseases given their shared vector ecology.